Fecal carriage of Extended Spectrum β-Lactamases (ESBL) Producing Escherichia coli and Klebsiella spp. among School Children in Pokhara, Nepal by Baral, Bharat Prasad et al.
Nepal Journal of Biotechnology. Dec.  2 018  Vol. 6, No. 1: 25-32    ISSN 2091-1130 (Print)/ISSN 2467-9319 (online) 
 ORIGINAL RESEARCH ARTICLE 
 ©NJB, Biotechnology Society of Nepal                              25                                                Nepjol.info/index.php/njb 
 
Fecal carriage of Extended Spectrum β-Lactamases (ESBL) 
Producing Escherichia coli and Klebsiella spp. among School 
Children in Pokhara, Nepal 
Bharat Prasad Baral1,2, Binita Koirala sharma2, Krishna Gurung1,  Ram Raja Gurung4, Hosuru Subramanava 
Supram2, Balkrishna Bhattachan3* 
1Pokhara Bigyan Thatha Prabidi Campus, Pokhara , Nepal 
2Manipal Teaching Hospital, Pokhara, Nepal 
3Siddhi Memorial Hospital, Bhaktapur, Nepal 
4Deurali-Janta Pharmaceuticals Pvt. Ltd., Kathmandu, Nepal 
Abstract 
Extended-spectrum β-lactamases (ESBL) producing microbes in recent years have been a major 
problem in developing countries like Nepal, with limited treatment options. This study aimed to 
determine the prevalence of ESBL producing E. coli and Klebsiella spp. in school children in 
Pokhara, Nepal. The study was conducted from June to October, 2015 at the microbiology 
laboratory of Manipal Teaching Hospital, Pokhara, Nepal. Antibiotic Susceptibility Test (AST) 
was done after isolation and identification of bacterial isolates. Then, presence of ESBL enzymes 
in E. coli and Klebsiella spp. were tested by combination disc diffusion test using cefotaxime and 
ceftazidime alone and with clavulanic acid. Out of total 309 school children, 211 (68%) bacterial 
isolates were detected from stool samples. Among them, E. coli and Klebsiella spp. were detected 
in 97 (46%) and 39 (19%) stool samples respectively. Bacteria isolated from 14 (5%) stool samples 
were multi-drug resistant (MDR) positive. After applying combined disk method, 88 (29%) 
isolates were found to be ESBL producer. Emerging prevalence rate of ESBL producing E. coli 
and Klebsiella spp. are major problem in medical history. Therefore, rapid need of surveillance 
for effective management of such MDR-strain is required. 
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Introduction  
Extended-spectrum β-lactamases (ESBL) 
producing organism was first isolated in 1983, 
Germany, since it has been increasingly reported 
worldwide [1, 2].  The prevalence of ESBL-
positive isolates depends upon wide range of 
environmental, genetic, geographical, age group, 
and type of infections [3]. Emerging and 
increasing incidence of ESBL related infections 
has been observed throughout the world [4]. 
ESBLs are Class A β-lactamases carbapenems 
and are often plasmid-mediated enzymes with 
various genotypes [1]. The most common 
genotypes are the SHV, TEM, and CTX-M types 
[5]. Other clinically important types include VEB, 
PER, BEL-1, BES-1, SFO-1, TLA, and IBC [6]. 
Enterobacteriaceae family of gram-negative 
organisms; in particular, K. pneumoniae, K. 
oxytoca and Escherichia coli produce ESBLs [7]. 
They are also produced by other gram-negative 
organisms, such as Acinetobacter baumannii, 
Proteus spp., Pseudomonas aeruginosa, and 
Salmonella spp. [8]. 
 Patients suffering from ESBL producers have 
high mortality, longer hospital stay, high health 
care cost, and longer antibiotic therapy as 
compared to those patients suffering from non-
ESBL producers [9]. Furthermore, they pose 
significant therapeutic challenges in the daily 
management of infectious diseases due to their 
resistance to additional classes of antibiotics 
reducing the effectiveness of alternative 
antimicrobial regimens [10]. Worldwide, several 
studies [1, 5, 6, 8] have been conducted but only 
a few data are available concerning the genetic 
characterization of clinical isolates from Nepal 
[7, 11]. The acquisition and expression of ESBL 
enzymes among E. coli and Klebsiella spp. have 
posed a serious public health problem. This 
study was conducted to determine the ESBL 
producing bacteria in school going children 
without any clinical symptoms to observe the 
fecal carriage.   
Study designing and setting   
The study was conducted in Pokhara Lekhanath 
Municipality-26, where samples were collected 
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from three government (n=147) and three private 
schools (n=176).  Children from 4 to 15 years 
were enrolled who were apparently healthy and 
not taking any antibiotics 1 week prior to our 
study. After taking written informed consent and 
questionnaire from their parents, stool samples 
were collected in a sterile screw-capped 
container. Demographic data like age, sex, 
antibiotic intake within 15 days, were included 
in questionnaire form. A total of 323 children 
were enrolled, where all children provided stool 
samples, except 14 who provided insufficient 
stool samples without any labeling. 
Sample collection and Processing  
Around one gram of fresh stool sample was 
collected in a clean, well labeled, and sterile 
screw-capped plastic container. Collected 
samples were kept in an icebox, transported 
within 1 hour, and processed immediately 
following Standard Operating Procedures (SOPs) 
of Microbiology to the laboratory of Manipal 
Teaching Hospital (MTH) in Pokhara, Nepal. If 
there was a delay in processing the specimens 
were kept in a freezer at 2–8°C. The general 
procedure of sample processing were explained 
in the flowchart (Figure 1). 
Isolation and identification of E. coli 
and Klebsiella spp.by culture method  
Stool samples were inoculated onto MacConkey 
agar plates, which were incubated at 37°C for 24 
hours. After proper incubation, plates were 
observed for the growth of the bacteria. Isolated 
colonies were sub-cultured in nutrient agar and 
then plates were incubated at 37°C for 24 hours. 
Gram-positive and negative bacteria were 
initially confirmed by gram staining and 
thereafter, identified by conventional 
biochemical tests such as (MRVP, Indole, 
motility, protease, citrate, & O/F). 
Antimicrobial Susceptibility Testing 
(AST) 
AST of all isolates was performed by Kirby 
Bauer's disc diffusion method and interpretation 
of the results was done as described in Clinical 
Laboratory Standard Institute (CLSI) guideline 
2016 [18]. For antibiotic susceptibility testing, 
antibiotic discs (HiMedia Laboratories Pvt. Ltd., 
India) cefotaxime (30μg), ceftazidime (30μg), 
gentamycin (10μg), imipenem (10μg), 
nitrofurantoin (300μg), norfloxacin (10μg), 
piperacillin-tazobactam (100μg/10μg), and 
amikacin (30μg) were used. Control strains of E. 
coli ATCC 25922 were used in parallel as a part 
of quality control. Organisms showing resistance 
towards two or more classes of antimicrobial 
agents were considered to be multidrug-resistant 
(MDR). 
Screening and Confirmation of ESBL 
producing Strains 
All the E. coli isolates were subjected to the 
screening test for ESBL detection. Screening test 
for ESBL detection was done according to the 
CLSI guidelines. Isolates showing inhibition 
zone size of ≤ 22 mm with ceftazidime (30 μg), ≤ 
25 mm with ceftriaxone (30 μg), and ≤ 27 mm 
with cefotaxime (30 μg) were interpreted as 
screening test positive for ESBL production [18].  
For the confirmatory test for ESBL, two or three 
colonies of organisms were suspended in 0.5 ml 
of sterile broth and the turbidity matched to 0.5 
McFarland. Using a sterile cotton swab the broth 
culture was uniformly swabbed on MHA. All the 
E. coli isolates which were resistant to at least 
ceftazidime, ceftriaxone and/or cefotaxime were 
subjected to the ESBL confirmatory test using 
ceftazidime (30 μg) and ceftazidime-clavulanic 
acid (30 μg & 10 μg) and the cefotaxime (30 μg) 
and cefotaxime-clavulanic acid (30 μg & 10 μg) 
combination disks. The tests were interpreted 
and a difference of 5 mm between zone of 
inhibition of a single disk and in combination 
with clavulanic acid (inhibitor) was confirmed to 
be produced by an ESBL positive isolate [18]. 
Klebsiella pneumoniae ATCC 700603 was used as a 
control strain. 
Statistical analysis  
Pearson's Chi-square test was used to determine 
the significant association of dependable 
variables. WinPepi software (version 11.65) was 
used for quantitative data analysis. A p-value < 
0.05 was considered to be statistically significant 
at 95 % CI. 
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Figure 1: Flowchart of isolation and identification of E. coli and Klebsiella spp. from collected stool samples 
 
Results 
As summarized in Table 1, in 143 females, E. 
coli and Klebsiella spp. were isolated from 43 
(30%) and 18 (16%) respectively. In 166 male 
children, E. coli and Klebsiella spp. were 
isolated from 54 (33%) and 21 (13%) 
respectively. E. coli and Klebsiella spp. were 
most frequently found in children aged 6-10 
years both in females (31% and 32%) and 
males (14% and 46%), respectively. 
Of the total samples tested, 211 (68.3%) 
bacterial isolates were detected.  Among them, 
E. coli and Klebsiella spp. were detected in 97 
(46%) and 39 (19%) stool samples respectively. 
Of the total tested samples, 14 (16%) isolates of 
bacteria were  
Figure 2. Antibiotic resistance pattern of 
Klebsiella spp.
 
0 
40 
17 
20 
10 
67 
44 
50 
Norfloxacin
Ceftazidime
Gentamicin
Amikacin
Imipenam
Piperacillin-…
Ceftaxime
Nitrofurantoin
Table 1.Age and sex wise distributions in E. coli and Klebsiella spp. in school children  
Gender 
Age (year) 
Female Male 
Total E. coli Klebsiella spp. Total E. coli Klebsiella spp. 
4-5 7 2 (29) 0 (0) 6 3 (50) 0 (0) 
6-10 104 32 (31) 15 (14) 127 41 (32) 19 (46) 
11-15 32 9 (28) 3 (9) 33 10 (30) 2 (20) 
Total 143 43 (30) 18 (16) 166 54 (33) 21 (13) 
Table 2. Distribution of E. coli and Klebsiella spp. on the basis of ESBL producer and MDR 
Bacterial Isolates 
 
Total no. 
isolates (%) 
(n =211) 
Multidrug resistance 
(MDR) isolates number 
(%) (n =14) 
ESBL screening 
positive (%) 
(n =116) 
ESBL producer 
confirm (%) 
(n =88) 
E. coli  97 (46) 9 (64) 84 (72) 74  (84) 
Klebsiella spp.   39 (19) 5 (36) 32 (10) 14  (16) 
Others gram-
negative bacteria 
27 (13) NT NT NT 
Gram-positive 
bacteria 
48 (23) NT NT NT 
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Figure 3: Antibiotic resistance pattern of E. coli. 
Figure 2 summarizes that Klebsiella spp. was 
resistance to piperacillin-tazobactam (67%); 
nitrofurantoin (50%) and cefotaxime (44%). As 
depicted in Figure 3, the resistance pattern of 
E. coli was also found highest in piperacillin-
tazobactam (62%) followed by norfloxacin 
(60%) and cefotaxime (50%) etc. found MDR 
strains, while 116  isolates were screened as 
ESBL positive. By combined disk method, 88 
isolates were confirmed to be ESBL producer. 
Among the total MDR bacteria, 9 (64%) were 
E. coli and 5 (36%) were Klebsiella spp., 74 
(84%) isolates of E. coli and 14 (16%) of 
Klebsiella spp. were confirmed as ESBL 
producer (Table 2). 
Discussion  
ESBL producing gram-negative bacilli, 
particularly K. pneumoniae and E.coli, recently 
arose worldwide in a hospital and 
Community-Acquired Infections (CAIs) as 
serious pathogens, and has been progressively 
rising. This upsurge introduces additional 
difficulties in treating patients affected by 
EBSLs since it puts at risk the activity of 
numerous wide-spectrum antibiotics [7]. The 
present study exhibits that out of the 211 
clinical isolates, 88 (42%) were found to be 
ESBL producers, and these results were in 
accordance with a previously conducted study 
[11, 18]. Additionally, the ratio of positive 
cases for the male to female children in this 
study was 1.2:1, which contrasted another 
study where the ratio for male to female 
patients was 1:2.2 [7]. However, this difference 
in the ratio may be due to a gender bias of 
male and female samples initially in both the 
experiments. Thus, gender may not play a role 
in ESBL susceptibility of a person. 
Furthermore, E. coli positive cases were found 
in 97 (31%) clinical isolates, which was the 
predominant organism in this case. 
Conversely, another study found E. coli to be 
positive in 81% of their samples, which is 
remarkably higher than that of our study [7]. 
The high occurrence of positive result may 
suggest that there is a possibility of normal 
flora of human E. coli. 
Anti-microbial Resistance (AMR) is a major 
public health problem in patient care in both 
developed and developing countries. 
Therefore, in this study, we analyzed eight 
different antibiotics. Among eight antibiotics, 
Piperacillin-Tazobactam resistant was 
predominant in both E. coli (62%) and K. 
pneumoniae (67%), which differed from 
previous studies [13–15]. Piperacillin-
Tazobactam is commonly used to treat intra-
abdominal, lower respiratory, urinary tract, 
and gynecological and skin/soft tissue 
infections, as well as for fever in patients with 
neutropenia [16].  
The predominance of the resistant bacteria for 
these antibiotics could imply that illnesses 
associated to E. coli & K. spp. are fairly 
prevalent in the Pokhara and have been 
treated just as normally. In addition, the rates 
of resistance to cefotaxime, ceftazidime, 
gentamycin, and amikacin for E. coli presented 
in this study are 50%, 60%, 10%, and 11% 
respectively. However, this contrasts another 
study, where the resistance of E. coli were 
found 99%, 78%, 29% and 4% to cefotaxime, 
ceftazidime, gentamycin, and amikacin 
respectively [17]. This may suggest that the E. 
coli collected from Nepal has not been exposed 
to the four antibiotics quite as much as in 
other more developed places, which could 
probably mean that it is still possible to more 
easily manage the ESBLs in Nepal effectively 
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compared to places with higher antibiotic 
exposure and resistance. From the eight 
antibiotics that were analyzed, Imipenem was 
the most effective drug; however, it should not 
be administered as the empirical drug unless 
the infection is life-threatening, since 
carbapenems are considered the drug of last 
resort. If this situation is not taken seriously 
and misuse the carbapenem drugs then 
carbapenem resistant bacteria may evolve. 
In this study, 4.5% MDR strains were detected, 
which was very low compared with other 
studies 64.0%, and 64.9% [19]. This may be the 
case due to the overexposure of the antibiotics 
to the bacteria in external environments and 
animals, whereas in the related district it may 
not be the case.  
Furthermore, 84% E. coli was confirmed as 
ESBL producer followed by K. pneumoniae, 
(9%) and K. oxytoca (7%). A similar result was 
found in the study where the researchers 
reported 91% E. coli and 8% K. pneumonia [7]. 
Conversely, the findings of another study [20] 
showed the variable result with E. coli isolates, 
33(9%) were ESBL producers. The 
identification of ESBL producing organisms is 
a major challenge in the clinical world and, 
due to the selective pressure caused by heavy 
use of expanded-spectrum cephalosporins, 
lapses in effective infection control measures 
and affinity of these enzymes for different 
substrates, outbreaks are increasing [21]. 
An antibacterial choice is often complicated by 
MDR leading to over-prescription and misuse 
of antibiotics. As indicated by the present and 
previous findings, it appears to be mandatory 
to include ESBL detection in routine 
laboratory practice so as to limit the rapid 
spread of ESBL producing organisms. AMR 
can be tackled by following continuously the 5 
steps viz. awareness; surveillance; 
stewardship; research & innovation; infection 
prevention & control accordance with the 
“One Health” concept in agriculture, 
veterinary, environment and human. 
Limitation of study:  
We couldn’t perform genotyping test and 
MBL test in bacterial isolates due to a limited 
resource and time limitation. 
Conclusions: 
The prevalence of ESBL producing E. coli and 
Klebsiella spp. was more. The preponderance 
of ESBL producing E. coli and Klebsiella spp. 
were resistant to the in-use antibiotics used 
from stool samples. Imipenem was the most 
potent antibiotic and could be the drug of 
choice for treatment of infections caused by 
ESBL strains. This clinical threat of raised up 
ESBL prevalence is creating significant 
therapeutic problems prompting an 
immediate need to formulate strategic policy 
initiatives to reduce their prevalence. 
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